Skip to content


Macrilen, Macimorelin Aeterna Zentaris (macimorelin) is a small molecule pharmaceutical. Macimorelin was first approved as Macrilen on 2017-12-20. It has been approved in Europe to treat endocrine diagnostic techniques. The pharmaceutical is active against growth hormone secretagogue receptor type 1. Macrilen's patent is valid until 2027-10-12 (FDA).
Trade Name Macimorelin Aeterna Zentaris
Common Name Macimorelin
Indication endocrine diagnostic techniques
Drug Class Prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides
Get full access now